Does the media refer more to BNTX or CNTA?

In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than BioNTech. MarketBeat recorded 3 mentions for Centessa Pharmaceuticals and 2 mentions for BioNTech. BioNTech's average media sentiment score of 0.85 beat Centessa Pharmaceuticals' score of 0.72 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CNTA or MRNA?

In the previous week, Moderna had 36 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 39 mentions for Moderna and 3 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Moderna's score of 0.37 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 15 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 9 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CNTA or ROIV?

In the previous week, Roivant Sciences had 6 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 9 mentions for Roivant Sciences and 3 mentions for Centessa Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.35 beat Centessa Pharmaceuticals' score of 0.72 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INSM or CNTA?

In the previous week, Insmed had 9 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 12 mentions for Insmed and 3 mentions for Centessa Pharmaceuticals. Insmed's average media sentiment score of 1.17 beat Centessa Pharmaceuticals' score of 0.72 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VTRS or CNTA?

In the previous week, Viatris and Viatris both had 3 articles in the media. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Viatris' score of 0.53 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Centessa Pharmaceuticals (CNTA) Competitors

$40.50 +0.32 (+0.80%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$40.71 +0.21 (+0.52%)

As of 06/23/2026 07:33 PM Eastern

Compare

CNTA vs. BNTX, MRNA, ROIV, INSM, and VTRS

Should you buy Centessa Pharmaceuticals stock or one of its competitors? MarketBeat compares Centessa Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Centessa Pharmaceuticals include BioNTech (BNTX), Moderna (MRNA), Roivant Sciences (ROIV), Insmed (INSM), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Centessa Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

BioNTech currently has a consensus price target of $129.56, indicating a potential upside of 42.97%. Centessa Pharmaceuticals has a consensus price target of $41.33, indicating a potential upside of 2.06%. Given BioNTech's stronger consensus rating and higher probable upside, equities research analysts clearly believe BioNTech is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Centessa Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.06	-$1.29B	-$5.88	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Centessa Pharmaceuticals has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than BioNTech. MarketBeat recorded 3 mentions for Centessa Pharmaceuticals and 2 mentions for BioNTech. BioNTech's average media sentiment score of 0.85 beat Centessa Pharmaceuticals' score of 0.72 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioNTech beats Centessa Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Moderna?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Moderna	-143.55%	-26.64%	-19.32%

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

In the previous week, Moderna had 36 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 39 mentions for Moderna and 3 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Moderna's score of 0.37 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	15 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	9 Negative mention(s)	0 Very Negative mention(s)	Neutral

Centessa Pharmaceuticals presently has a consensus target price of $41.33, suggesting a potential upside of 2.06%. Moderna has a consensus target price of $36.60, suggesting a potential downside of 40.00%. Given Centessa Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Centessa Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Centessa Pharmaceuticals has higher earnings, but lower revenue than Moderna. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Moderna	$1.94B	12.45	-$2.82B	-$8.15	N/A

Summary

Centessa Pharmaceuticals beats Moderna on 9 of the 15 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Roivant Sciences?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Centessa Pharmaceuticals has higher earnings, but lower revenue than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Roivant Sciences	$8.26M	2,804.80	-$299.77M	-$0.60	N/A

Centessa Pharmaceuticals currently has a consensus target price of $41.33, indicating a potential upside of 2.06%. Roivant Sciences has a consensus target price of $33.59, indicating a potential upside of 4.29%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Roivant Sciences had 6 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 9 mentions for Roivant Sciences and 3 mentions for Centessa Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.35 beat Centessa Pharmaceuticals' score of 0.72 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Roivant Sciences beats Centessa Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Centessa Pharmaceuticals' return on equity of -60.37% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

In the previous week, Insmed had 9 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 12 mentions for Insmed and 3 mentions for Centessa Pharmaceuticals. Insmed's average media sentiment score of 1.17 beat Centessa Pharmaceuticals' score of 0.72 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Centessa Pharmaceuticals has lower revenue, but higher earnings than Insmed. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.51	-$1.28B	-$5.75	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Insmed currently has a consensus price target of $211.86, indicating a potential upside of 107.40%. Centessa Pharmaceuticals has a consensus price target of $41.33, indicating a potential upside of 2.06%. Given Insmed's stronger consensus rating and higher probable upside, research analysts clearly believe Insmed is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

Insmed and Centessa Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Viatris currently has a consensus price target of $17.50, indicating a potential upside of 11.11%. Centessa Pharmaceuticals has a consensus price target of $41.33, indicating a potential upside of 2.06%. Given Viatris' stronger consensus rating and higher possible upside, research analysts clearly believe Viatris is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Centessa Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

79.9% of Viatris shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Viatris and Viatris both had 3 articles in the media. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat Viatris' score of 0.53 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Centessa Pharmaceuticals beats Viatris on 7 of the 13 factors compared between the two stocks.

Get Centessa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTA vs. The Competition

Export

Metric	Centessa Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.21B	$2.96B	$6.44B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-22.63	18.43	24.66	23.99
Price / Sales	N/A	327.41	528.64	107.77
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	10.33	4.11	10.79	6.50
Net Income	-$197.53M	$64.45M	$3.56B	$336.88M
7 Day Performance	1.58%	1.41%	1.01%	-0.14%
1 Month Performance	1.89%	1.04%	0.43%	0.77%
1 Year Performance	185.21%	23.88%	29.71%	28.49%

Centessa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTA Centessa Pharmaceuticals	1.4492 of 5 stars	$40.50 +0.8%	$41.33 +2.1%	+211.5%	$6.21B	N/A	N/A	200	High Trading Volume
BNTX BioNTech	4.5219 of 5 stars	$89.50 -1.4%	$129.56 +44.8%	-12.0%	$22.63B	$3.25B	N/A	7,807
MRNA Moderna	1.2297 of 5 stars	$55.40 +6.3%	$36.60 -33.9%	+137.6%	$21.98B	$1.94B	N/A	4,700
ROIV Roivant Sciences	1.8618 of 5 stars	$30.41 +1.3%	$33.59 +10.5%	+180.1%	$21.87B	$8.26M	N/A	860	Positive News
INSM Insmed	3.4486 of 5 stars	$95.52 -2.0%	$211.86 +121.8%	-3.1%	$20.70B	$606.42M	N/A	1,664	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Centessa Pharmaceuticals (CNTA) Competitors

CNTA vs. BNTX, MRNA, ROIV, INSM, and VTRS

How does Centessa Pharmaceuticals compare to BioNTech?

Summary

How does Centessa Pharmaceuticals compare to Moderna?

Summary

How does Centessa Pharmaceuticals compare to Roivant Sciences?

Summary

How does Centessa Pharmaceuticals compare to Insmed?

Summary

How does Centessa Pharmaceuticals compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTA vs. The Competition

Centessa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Centessa Pharmaceuticals (CNTA) Competitors

CNTA vs. BNTX, MRNA, ROIV, INSM, and VTRS

How does Centessa Pharmaceuticals compare to BioNTech?

Do analysts rate BNTX or CNTA?

Which has higher earnings and valuation, BNTX or CNTA?

Is BNTX or CNTA more profitable?

Do institutionals & insiders have more ownership in BNTX or CNTA?

Which has more volatility & risk, BNTX or CNTA?

Does the media refer more to BNTX or CNTA?

Summary

How does Centessa Pharmaceuticals compare to Moderna?

Is CNTA or MRNA more profitable?

Do institutionals and insiders believe in CNTA or MRNA?

Which has more volatility and risk, CNTA or MRNA?

Does the media refer more to CNTA or MRNA?

Do analysts rate CNTA or MRNA?

Which has preferable earnings and valuation, CNTA or MRNA?

Summary

How does Centessa Pharmaceuticals compare to Roivant Sciences?

Which has more volatility & risk, CNTA or ROIV?

Do institutionals & insiders have more ownership in CNTA or ROIV?

Is CNTA or ROIV more profitable?

Which has better valuation & earnings, CNTA or ROIV?

Do analysts recommend CNTA or ROIV?

Does the media prefer CNTA or ROIV?

Summary

How does Centessa Pharmaceuticals compare to Insmed?

Is INSM or CNTA more profitable?

Does the media refer more to INSM or CNTA?

Do institutionals and insiders have more ownership in INSM or CNTA?

Which has stronger earnings and valuation, INSM or CNTA?

Which has more volatility and risk, INSM or CNTA?

Do analysts recommend INSM or CNTA?

Summary

How does Centessa Pharmaceuticals compare to Viatris?

Do analysts prefer VTRS or CNTA?

Which has better earnings & valuation, VTRS or CNTA?

Which has more volatility and risk, VTRS or CNTA?

Is VTRS or CNTA more profitable?

Do institutionals & insiders believe in VTRS or CNTA?

Does the media favor VTRS or CNTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTA vs. The Competition

Centessa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools